Hyperparathyroidism Pipeline 2026: Transformative Clinical Progress Driven by 3+ Global Innovators -

Author : k kumar | Published On : 03 Aug 2026

As Hyperparathyroidism continues to rise globally and significantly contributes to comorbidities such as diabetes, cardiovascular disorders, and certain cancers, the need for safer and more effective therapeutic interventions is intensifying. According to DelveInsight, the Hyperparathyroidism pipeline includes 25+ pharmaceutical and biotech companies advancing 30+ therapeutic candidates. These assets span multiple stages of clinical and preclinical development, reflecting strong innovation and sustained efforts to address a critical and growing healthcare burden.

DelveInsight's "Hyperparathyroidism Pipeline Insight 2026" report delivers an in-depth strategic analysis of the current R&D landscape. It evaluates clinical trial developments, emerging drug candidates, mechanisms of action, competitive dynamics, and strategic initiatives by key players. The report acts as an essential resource for researchers, investors, and healthcare stakeholders seeking actionable intelligence on the evolving Hyperparathyroidism Therapeutics Market and the innovations shaping its future.

Explore the Cutting-Edge Landscape of Hyperparathyroidism Drug Development @ https://www.delveinsight.com/report-store/hyperparathyroidism-pipeline-insight

Key Takeaways from the Hyperparathyroidism Pipeline Report

DelveInsight’s Hyperparathyroidism pipeline report highlights a dynamic development landscape, with 3+ major companies progressing 3+ promising therapies for Hyperparathyroidism treatment.

In April 2025, Parsabiv (etelcalcetide) received formal approval for the treatment of secondary hyperparathyroidism (SHPT) in adult patients undergoing dialysis. This intravenous calcimimetic, administered three times weekly after dialysis sessions, demonstrated substantial reductions in PTH levels during Phase III trials.

Leading Hyperparathyroidism companies, including Shanghai Hengrui Pharmaceutical Co., Ltd., Shaanxi Micot Technology Limited Company, Crinetics Pharmaceuticals, Inc., Pathalys Pharma, and others, are actively advancing innovative drug candidates aimed at improving patient outcomes.

Notable pipeline therapies such as SHR6508, MT1013, and other emerging candidates are currently progressing through various stages of development.

Hyperparathyroidism Overview:

Hyperparathyroidism is a disorder characterized by excessive secretion of parathyroid hormone (PTH) from one or more of the parathyroid glands. These small glands, located near the thyroid gland at the base of the neck, play a crucial role in regulating calcium and phosphate balance. Under normal physiological conditions, PTH maintains calcium equilibrium by stimulating bone resorption, enhancing renal calcium retention, promoting phosphate excretion, and facilitating intestinal calcium absorption through vitamin D activation. In hyperparathyroidism, elevated PTH levels result in hypercalcemia, which may lead to bone demineralization, kidney stone formation, and calcium deposition in soft tissues and blood vessels.

Primary hyperparathyroidism is often identified incidentally during routine laboratory testing, as early stages may be asymptomatic. When symptoms manifest, they are typically associated with elevated calcium levels or bone mineral loss. Clinical features may include osteoporosis, kidney stones, frequent urination, abdominal discomfort, fatigue, muscle weakness, depression, cognitive impairment, nausea, vomiting, constipation, joint pain, confusion, and increased thirst. In certain cases, patients remain asymptomatic and are diagnosed during unrelated evaluations.

Download the Hyperparathyroidism sample report to know in detail about the Hyperparathyroidism treatment market

Hyperparathyroidism Pipeline Analysis

The Hyperparathyroidism pipeline insights report 2026 provides:

Comprehensive profiling of companies developing therapies within the Hyperparathyroidism Market.

Classification of therapeutic candidates by development stage: early, mid, and late phase.

Identification of key organizations engaged in targeted therapy development, including both active and inactive (paused or discontinued) programs.

Detailed evaluation of emerging Hyperparathyroidism drugs based on:

Stage of development
Hyperparathyroidism Route of administration
Target receptor
Monotherapy vs. combination therapy
Hyperparathyroidism Mechanism of action
Molecular type

In-depth analysis of:

Strategic collaborations between companies and academic institutions
Hyperparathyroidism licensing agreements
Funding and investment activities supporting future Hyperparathyroidism market growth

Unlock key insights into emerging Hyperparathyroidism therapies and market strategies

Hyperparathyroidism Emerging Drugs

1. Kyowa Hakko Kirin

Drug Candidate

Evocalcet (KHK7580 / Orkedia)

Indication / Population

Secondary hyperparathyroidism (SHPT) in dialysis patients
Primary hyperparathyroidism (PHPT) / Hypercalcemia associated with parathyroid carcinoma

Mechanism of Action (MOA)

Calcimimetic – allosteric positive modulator of the calcium-sensing receptor (CaSR), reducing parathyroid hormone (PTH) secretion.

Clinical Trials & Phases

Phase 3 (SHPT): Japanese phase III trials for SHPT in patients on maintenance hemodialysis have been conducted, meeting primary efficacy endpoints compared with active control (cinacalcet). Trial NCT02549391.
Phase 3 (PHPT / Hypercalcemia): Initiated (open-label) for patients with primary hyperparathyroidism or parathyroid carcinoma with hypercalcemia who cannot undergo surgery. jRCT or ClinicalTrials.gov details reference early steps.
Phase 2 (SHPT): Evocalcet demonstrated dose-related PTH reduction vs placebo in a Phase 2b study in Japanese SHPT patients.
Phase 1 PK/PD: Single/multiple dose PK/PD in healthy subjects reported (China site, not Japan) but relevant for safety profiling.

Latest Developments / News

Evocalcet marketed in Japan for SHPT; supplemental applications submitted for broader hyperparathyroidism indications including PHPT and hypercalcemia.
Clinical evidence supports safety and PTH reduction with a favorable GI adverse event profile compared to older calcimimetics.

2. EA Pharma (Subsidiary of Eisai / Ajinomoto heritage)

Drug Candidate

Upacicalcet (AJT240 / Upasita® IV)

Indication / Population

Secondary hyperparathyroidism (SHPT) in hemodialysis patients.

Mechanism of Action (MOA)

Intravenous calcimimetic that agonizes the calcium-sensing receptor to suppress excessive PTH secretion.

Clinical Trials & Phases

Phase 1/2: Initial Phase I/II trials established dose-dependent PTH reductions and tolerability in hemodialysis patients with SHPT.
Phase 3 (Japan): Completed placebo-controlled Phase 3 studies showing reduced intact PTH (iPTH) and safety; approved in Japan (Upasita) in 2021.
- NCT03801980 is an example Phase 3 placebo-controlled study.

Latest Developments / News

Sanwa Kagaku & Kissei co-promotion in Japan; Pathalys Pharma licensed ex-Japan rights for global Phase 3 development.
Post-hoc data suggest upacicalcet impacts phosphate and albumin metabolism and may offer bone metabolism benefits beyond PTH suppression.

3. Takeda Pharmaceutical Company

Drug Candidate

rhPTH (1-84) (Recombinant human parathyroid hormone)

Indication

Chronic hypoparathyroidism (not a hyperparathyroid excess but relevant to parathyroid pathology)

Mechanism of Action (MOA)

Hormone replacement therapy providing exogenous PTH to correct low PTH states.

Clinical Trial (Japan)

Phase 3 Open-label Trial: rhPTH (1-84) evaluated in Japanese subjects with chronic hypoparathyroidism. jRCT2080224751 – Phase 3, dosing over 26 weeks.

Notes

Although not focused on hyper-excess, this is relevant to companies active in parathyroid hormone modulation in Japan.

As of current publicly indexed data, no standalone Korean pharmaceutical company has been reported to be the primary sponsor of an interventional Phase 1-3 clinical trial in hyperparathyroidism (primary or secondary) indexed in major registries or press releases. Many Korean pharma firms co-market or out-license compounds (e.g., upacicalcet licensure) but are not leading sponsor roles in registered hyperparathyroid drug trials according to available clinical trial registries.

Key Insight:

Upacicalcet ex-Japan license includes Korea territory, but trials run by Pathalys Pharma / EA Pharma; Korean companies are not primary sponsors in registries.

Clinical Context Rather Than Sponsorship

Maxacalcitol – a vitamin D analog used in Taiwan and Japan for SHPT (approved drug), but no major new interventional trial sponsorship by a Taiwanese biotech/pharma company has been indexed specifically as sponsor for Phase 1-3 hyperparathyroidism drug trials outside of academic or investigator-initiated work.

Academic/PK/PD Studies

Pharmacokinetic comparison studies include Taiwanese subjects for maxacalcitol, indicating regional pharmacology interest but not a company-sponsored drug trial targeting hyperparathyroidism.

SHR6508: Shanghai Hengrui Pharmaceutical Co., Ltd.

SHR6508 is an investigational small-molecule calcimimetic developed by Shanghai Hengrui Pharmaceutical Co., Ltd. for treating secondary hyperparathyroidism (SHPT) in chronic kidney disease patients undergoing hemodialysis. The therapy functions as a calcium-sensing receptor agonist, modulating calcium signaling within parathyroid cells to suppress excessive PTH secretion. While its complete molecular profile is still under investigation, SHR6508 represents a targeted approach aimed at restoring hormonal balance. The candidate is currently in Phase III clinical development.

MT1013: Shaanxi Micot Technology Limited Company

MT1013 is an innovative therapy under development by Shaanxi Micot Technology Limited Company for secondary hyperparathyroidism (SHPT) associated with chronic kidney disease. As a parathyroid hormone receptor type 1 (PTH1R) antagonist, MT1013 targets PTH signaling pathways to regulate elevated hormone levels. By interfering with calcium-dependent signaling mechanisms in parathyroid cells, the therapy may help reduce abnormal PTH secretion in patients with impaired renal function. MT1013 is presently in Phase II clinical trials.

Hyperparathyroidism Pipeline Therapeutic Assessment

Hyperparathyroidism Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Hyperparathyroidism By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Hyperparathyroidism Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hyperparathyroidism Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Hyperparathyroidism therapies and key Hyperparathyroidism companies

Table of Contents

Report Introduction
Executive Summary
Hyperparathyroidism Current Treatment Patterns
Hyperparathyroidism - DelveInsight's Analytical Perspective
Therapeutic Assessment
Hyperparathyroidism Late-Stage Products (Phase-III)
Hyperparathyroidism Mid-Stage Products (Phase-II)
Early Stage Products (Phase-I)
Pre-clinical Products and Discovery Stage Products
Inactive Products
Dormant Products
Hyperparathyroidism Discontinued Products
Hyperparathyroidism Product Profiles
Hyperparathyroidism Key Companies
Hyperparathyroidism Key Products
Dormant and Discontinued Products
Hyperparathyroidism Unmet Needs
Hyperparathyroidism Future Perspectives
Hyperparathyroidism Analyst Review
Appendix
Report Methodology

Request the sample PDF to get detailed insights about the Hyperparathyroidism pipeline reports

About DelveInsight

DelveInsight is a specialized Business Consulting and Market Research firm focused exclusively on the life sciences sector. The company supports pharmaceutical and biotechnology organizations with comprehensive, end-to-end solutions designed to enhance strategic decision-making and overall

Contact Info:
Kanishk Kumar
[email protected]
+14699457679